Quarterly report · Q1
4521.TEDINET S100OXC2
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥76.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.5bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥4.4bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥4.3bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.7bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.0bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.7bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥3.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥165.1bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥165.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥163.3bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥27.2bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥26.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥137.9bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥138.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥135.7bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥60.0bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥61.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥76.91 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥251.43 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.78 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 83.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥17.6bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥17.6bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥615m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥615m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥295m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥18.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥18.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥4.1bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥17.9bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥17.9bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥4.1bn |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥589m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥589m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥299m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥18.5bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥18.5bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥4.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 372
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales of finished goods and merchandise | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | - | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration_ReportableSegmentsMember | 17088000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration | 17088000000 | JPY |
| Royalty | CurrentYTDDuration_jpcrp040300-q1r_E00935-000MedicineReportableSegmentsMember | 494000000 | JPY |
| Royalty | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | - | JPY |
| Royalty | CurrentYTDDuration_ReportableSegmentsMember | 494000000 | JPY |
| Royalty | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Royalty | CurrentYTDDuration | 494000000 | JPY |
| Other income | CurrentYTDDuration_jpcrp040300-q1r_E00935-000MedicineReportableSegmentsMember | - | JPY |
| Other income | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | 615000000 | JPY |
| Other income | CurrentYTDDuration_ReportableSegmentsMember | 615000000 | JPY |
| Other income | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Other income | CurrentYTDDuration | 615000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00935-000MedicineReportableSegmentsMember | 17582000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | 615000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 18197000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Revenues from external customers | CurrentYTDDuration | 18197000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00935-000MedicineReportableSegmentsMember | - | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | - | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | - | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Transactions with other segments | CurrentYTDDuration | - | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E00935-000MedicineReportableSegmentsMember | 17582000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | 615000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 18197000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Net sales | CurrentYTDDuration | 18197000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E00935-000MedicineReportableSegmentsMember | 3760000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E00935-000RealEstateReportableSegmentsMember | 295000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 4056000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Operating income | CurrentYTDDuration | 4056000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の4の7第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第103期第1四半期(自 2022年4月1日 至 2022年6月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)科研製薬株式会社 | |
| Company name in english cover page | FilingDateInstant | KAKEN PHARMACEUTICAL CO., LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 堀 内 裕 之 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都文京区本駒込二丁目28番8号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03(5977)5007(ダイヤルイン) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経理部長 伊 東 誠 司 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都文京区本駒込二丁目28番8号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03(5977)5007(ダイヤルイン) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)経理部長 伊 東 誠 司 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00935 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |